Home » Catalent Forms Strategic Alliance with PAREXEL
Catalent Forms Strategic Alliance with PAREXEL
Catalent Pharma announced a global alliance with PAREXEL International to help streamline the clinical trial supply process. The result of years of collaboration, the alliance will provide a seamless, fully integrated service offering to ensure the timely and efficient delivery of clinical trial materials.
"As clinical trials become more complex, we feel it is imperative to help sponsors devise supply strategies and organize consistent manufacturing, packaging, and delivery of trial-related supplies to locations around the world," stated Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Clinical Supply Services at Catalent. "PAREXEL, with its extensive and unparalleled track record in clinical development, is the ideal partner for Catalent in this alliance, which will enable our customers to compete more effectively in the global marketplace."
"One of the most important steps in creating a strong, efficient clinical trial material supply chain is selecting a partner with innovative clinical packaging solutions and established global operations to oversee and coordinate all aspects of each critical supply chain stage," commented Kurt Norris, Corporate Vice President, Clinical Logistics Services, PAREXEL. "In establishing this alliance with Catalent, we have chosen a partner that is uniquely positioned to help biopharmaceutical companies reach critical development milestones through more efficient delivery of clinical trial supplies."
The alliance will provide fully integrated services and technologies across the entire clinical trial material supply chain spectrum, supporting all supply aspects in clinical development programs including: planning and development of supply strategies; material supply and demand forecasting; central and local clinical trial and ancillary material sourcing; innovative clinical manufacturing and leading clinical trial packaging solutions; worldwide regulatory and import/export management; global and local storage as well as distribution to trial sites; depot, site and patient inventory management; and material return and destruction/disposition.
Merck Stops Development of Parkinson’s DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesn’t work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »